U.S. Metals and Mining Stock News

NasdaqGS:ARVN
NasdaqGS:ARVNPharmaceuticals

Arvinas (ARVN) Q1 Loss Of US$0.90 Per Share Challenges Bullish Margin Narratives

Arvinas (ARVN) opened Q1 2026 with revenue of US$15.6 million and a basic EPS loss of US$0.90, alongside trailing twelve month revenue of US$89.4 million and a net loss of US$221.3 million. Over recent quarters the company has seen quarterly revenue move from US$188.8 million in Q1 2025 to US$15.6 million in Q1 2026, while basic EPS has shifted from a profit of US$1.14 per share in Q1 2025 to a loss of US$0.90. This sets up a results season in which investors may focus on how margins evolve...
NasdaqGS:MIDD
NasdaqGS:MIDDMachinery

Middleby Spin Off Of Midera Reshapes Growth Story And Valuation

Middleby is spinning off its Food Processing segment as Midera Food Processing Inc., creating two independent public companies. The newly named Midera will have its own management team, strategic roadmap, and three year financial guidance. The spin off includes a set timetable, with Midera common stock planned to begin trading on a specified future date. For investors following NasdaqGS:MIDD, this move reshapes how you think about the stock. Middleby shares recently closed at $147.45, with...
NYSEAM:CMCL
NYSEAM:CMCLMetals and Mining

Caledonia Mining (CMCL) Is Up 8.7% After Margin Gains Offset Lower Output In Q1 2026 Results – Has The Bull Case Changed?

Caledonia Mining Corporation Plc has reported its first-quarter 2026 results, with gold production at the Blanket Mine falling to 14,767 ounces from 18,671 ounces a year earlier, while sales rose to US$66.43 million and net income increased to US$15.85 million, alongside a maintained quarterly dividend of US$0.14 per share. Despite lower output, Caledonia’s higher realized gold prices, sharply higher earnings per share, stronger free cash flow and ongoing Bilboes project progress, together...
NYSE:MRSH
NYSE:MRSHInsurance

A Look At Marsh & McLennan (MRSH) Valuation As Project Leapfrog Showcases New AI Risk Capabilities

Marsh & McLennan Companies (MRSH) is piloting Project Leapfrog, an AI powered risk strategy tool that gives select clients real time guidance on corporate risk and puts the stock’s insurance analytics capabilities in sharper focus for investors. See our latest analysis for Marsh & McLennan Companies. The share price has come under pressure recently, with a 30 day share price return down 8.3% and year to date share price return down 12.79%, while the 1 year total shareholder return has...
NYSE:HLX
NYSE:HLXEnergy Services

Has The Helix Energy Solutions Group (HLX) Rally Left Limited Upside For Investors?

Evaluating whether Helix Energy Solutions Group at around US$10.14 offers good value, or whether the easy gains are behind it, starts with understanding how the current price lines up against its fundamentals. The stock has returned 2.9% over the past week, 3.6% over the past month, 58.4% year to date and 50.9% over the last year, which naturally raises questions about how much of the story is already reflected in the share price. Recent coverage has focused on Helix Energy Solutions Group...
NYSE:PH
NYSE:PHMachinery

Is It Too Late To Consider Parker-Hannifin (PH) After Its Recent Share Price Pullback?

Investors may be wondering if Parker-Hannifin, at around US$882 per share, still offers value or if most of the opportunity is already priced in. The stock has pulled back recently, with the share price down 2.2% over the past week and down 10.8% over the past month, although the 1-year return is 31.9% and the 3-year return is 175.3%. Recent coverage has focused on Parker-Hannifin as a large industrial supplier and on how investors are reassessing established industrial stocks after strong...
NYSE:HG
NYSE:HGInsurance

A Look At Hamilton Insurance Group (HG) Valuation After Strong One Year Shareholder Returns

Event overview and recent share performance Hamilton Insurance Group (HG) has attracted fresh attention after recent trading saw the stock close at US$30.27, with returns up about 0.3% over the past week but down around 2% over the past month. See our latest analysis for Hamilton Insurance Group. Zooming out, Hamilton Insurance Group’s share price return is up 11% year to date, while the 1 year total shareholder return of 58.7% suggests earlier investors have already seen strong gains, even...
NasdaqCM:SWMR
NasdaqCM:SWMRAerospace & Defense

How Swarmer’s Turnkey Drone Interception Push Could Reframe the SWMR Defense Investment Story

Earlier this week, Swarmer Inc. announced a collaboration with X-Drone, Norda Dynamics and Kara Dag Technologies to integrate detection, counter-drone and targeting systems into its collaborative autonomy platform, creating an end-to-end service to intercept Group 1–3 unmanned aerial vehicles and unmanned surface vessels up to eight meters long. This move effectively elevates Swarmer from a pure software provider to a coordinator of full-site defense solutions that can operate without a...
NasdaqGS:AKAM
NasdaqGS:AKAMIT

Why Akamai (AKAM) Is Up 32.1% After Anthropic AI Deal And Share Buyback Progress

In early May 2026, Akamai Technologies reported first-quarter 2026 results showing higher sales than a year earlier but lower net income and earnings per share, confirmed new revenue guidance for the second quarter and full year 2026, and disclosed further progress on its US$1.03 billion share repurchase program. Akamai also announced a seven-year, US$1.80 billion AI infrastructure agreement with Anthropic and new API security capabilities, underscoring its push into AI-focused cloud and...
NYSE:ARW
NYSE:ARWElectronic

Arrow Electronics Remote Lab Service Aims To Deepen Engineering Engagement

Arrow Electronics (NYSE:ARW) has introduced Digital Test Drive, a cloud-based remote engineering service. The service allows users to access and test hardware remotely through secure connections to Arrow’s engineering labs. Digital Test Drive is intended to reduce friction from kit availability, shipping logistics, and on-site setup. Arrow Electronics (NYSE:ARW) operates as a global distributor and solutions provider for electronic components and enterprise computing products. With Digital...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (VKTX) Valuation Revisited After New VK2735 Phase 2 Obesity Data Spurs Investor Interest

Viking Therapeutics (VKTX) drew fresh attention after presenting new Phase 2 data on its oral obesity drug candidate VK2735 at the European Congress on Obesity. The company highlighted weight loss efficacy, dose response, and safety over a 13-week period. See our latest analysis for Viking Therapeutics. Despite the fresh VK2735 data, Viking Therapeutics’ share price return has been mixed recently, with a 1-day gain of 1.26% and the 30-day share price return down 9.41%. However, the 1-year...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Assessing Old National Bancorp (ONB) Valuation After Recent Share Price Weakness

Why Old National Bancorp (ONB) is on investors’ radar today Old National Bancorp (ONB) has drawn fresh attention after recent trading left the stock with a year to date gain of 3.9% and a 1 year total return of 6.5%, despite softer recent returns. See our latest analysis for Old National Bancorp. Recent trading has been softer, with the share price down 2.94% over the last day and 4.60% over the past week. However, the 3 year total shareholder return of 96.69% and 5 year total shareholder...
NasdaqGS:FRMI
NasdaqGS:FRMISpecialized REITs

Fermi Leadership Showdown Raises Questions Over Valuation And Future Direction

Fermi (NasdaqGS:FRMI) is facing an escalating leadership and governance clash after the Board terminated former CEO Toby Neugebauer for cause. Neugebauer is now seeking to replace the Board and push for a company sale, moves that the current directors have publicly rejected. Major shareholder Caddis Capital has aligned with the Board, opposing a forced sale and backing the existing strategic direction. For investors following Fermi (NasdaqGS:FRMI), this governance fight sits on top of...
NYSE:MPC
NYSE:MPCOil and Gas

Is Marathon Petroleum (MPC) Still Attractively Priced After Its Strong 2024 Share Price Rally

Wondering whether Marathon Petroleum at US$251.99 still offers value, or if most of the upside is already in the price? This article walks through what the current share price could be implying. The stock has been strong over multiple periods, with a decline of 3.3% over the last week, a 13.2% gain over the last month, a 52.6% return year to date and a 58.1% return over the past year. The three year return sits at 150.1%, and the five year return is a very large gain. Recent coverage has...
NYSE:MD
NYSE:MDHealthcare

Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?

Pediatrix Medical Group, Inc. reported past first-quarter 2026 results with sales of US$476.2 million and net income of US$29.57 million, alongside higher basic and diluted earnings per share from continuing operations than a year earlier. The company’s stronger-than-expected adjusted EPS, reaffirmed full-year adjusted EBITDA outlook, and benefits from pricing and payer mix highlight improving operational execution despite modest volume declines. We’ll now examine how reaffirmed full-year...
NasdaqGS:GTX
NasdaqGS:GTXAuto Components

Is It Too Late To Consider Garrett Motion (GTX) After A 152% One Year Surge?

Investors may be wondering if Garrett Motion at around US$29.57 is still offering value after a strong run, or if they might be late to the story. The stock has delivered returns of 13.1% over the past week, 51.8% over the past month, 70.1% year to date and 152.2% over the past year, putting it firmly on many investors' radars. Recent coverage has focused on Garrett Motion's role in the Auto Components sector and how investors are reassessing companies involved in vehicle technology and...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

Assessing Corsair Gaming (CRSR) Valuation After Profit Return And Recent Earnings Turnaround

Corsair Gaming earnings and new share registration draw investor focus Corsair Gaming (CRSR) has reported a shift from a net loss to net income in its latest quarter, and has filed a shelf registration for common stock related to its employee stock ownership plan. See our latest analysis for Corsair Gaming. The latest quarter’s swing to net income has come alongside strong recent momentum in the stock, with a 30-day share price return of 31.81% and a 90-day share price return of 51.21%...
NYSE:AEM
NYSE:AEMMetals and Mining

Is It Time To Reassess Agnico Eagle Mines (AEM) After An 86% One-Year Surge?

If you are wondering whether Agnico Eagle Mines at US$197.05 is still offering value after a strong run, it helps to step back and look at what the recent numbers and news are really telling you about the stock. The share price has delivered a 10.6% gain over the past week, while the stock is down 9.9% over the past month, up 15.6% year to date and up 86.1% over the last year. These moves can change how the market is thinking about both upside potential and risk. Recent coverage has focused...
NasdaqGS:LNT
NasdaqGS:LNTElectric Utilities

Alliant Energy (LNT) Valuation Check After Q1 Earnings Beat And Reaffirmed 2026 Guidance

Alliant Energy (LNT) shares are in focus after the utility reported first quarter 2026 earnings and reaffirmed its full year earnings guidance, giving investors fresh data on revenue, profits, and ongoing EPS expectations. See our latest analysis for Alliant Energy. The first quarter earnings and reaffirmed 2026 EPS guidance come after a period where the share price has a year to date gain of 10.67%, while the 1 year total shareholder return is 23.83%, suggesting that momentum has been...
NYSE:USB
NYSE:USBBanks

Is It Too Late To Consider U.S. Bancorp (USB) After Its Strong One Year Rally?

Wondering if U.S. Bancorp at around US$54.48 is still offering value, or if most of the easy gains are already behind it. The stock is up 1.0% year to date and 28.0% over the past year, even though it has slipped about 2.0% over the past week and 2.1% over the past month. This suggests the recent pullback sits against a much stronger longer term return profile. Recent coverage has focused on U.S. Bancorp's position among large U.S. banks and how investors are reassessing risk and reward for...
NYSE:MUX
NYSE:MUXMetals and Mining

Assessing McEwen (MUX) Valuation After Profitable Q1 And Los Azules Growth Plans

What McEwen’s Q1 earnings mean for investors now McEwen (MUX) reported a profit in Q1 2026, supported by higher revenue that was associated with firmer gold and silver prices and improved operations. The company also highlighted its production growth objectives and reported progress at the Los Azules copper project. See our latest analysis for McEwen. The Q1 earnings news has arrived after a strong run, with McEwen’s share price up 23.69% over the past week and 40.04% year to date. Its 1 year...
NYSE:FDS
NYSE:FDSCapital Markets

FactSet And Valutico Link Private Market Valuations To Support FDS Story

FactSet Research Systems (NYSE:FDS) has launched a new partnership with Valutico to integrate valuation workflows for private capital markets. The collaboration connects portfolio monitoring, valuation modeling, and reporting in a single system for private asset investors. The move addresses growing industry pressure for more frequent and transparent private market valuations. FactSet Research Systems, trading at $215.92, has faced a challenging share price path, with the stock down 24.2%...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives

Catalyst Pharmaceuticals (CPRX) opened Q1 2026 with total revenue of US$149.4 million and basic EPS of US$0.52, setting a clear marker for how the year is starting. The company has seen quarterly revenue range from US$141.4 million in Q1 2025 to US$152.6 million in Q4 2025, while basic EPS moved between US$0.43 and US$0.47 over that period, giving you a solid view of how the top and bottom line have been tracking into the latest print. With a trailing net profit margin of 37.1% and earnings...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story

Rhythm Pharmaceuticals presented new clinical data on setmelanotide in adults with acquired hypothalamic obesity at the 2026 European Congress of Endocrinology. The data showed meaningful BMI reductions and improved cardiometabolic outcomes in treated adults. These findings follow recent pediatric efficacy results shared at the PES Annual Meeting, adding to the evidence base for IMCIVREE across different patient groups. The updates arrive shortly after regulatory approvals and commercial...